AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

BioMarin Pharmaceutical I... (BMRN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

65.01

0.16 (0.25%)

At close: Feb 18, 2025, 3:59 PM

64.86

-0.23%

After-hours: Feb 18, 2025, 04:00 PM EST

undefined% (undefined)

Bid	61
Market Cap	12.39B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	1.66
PE Ratio (ttm)	39.16
Forward PE	n/a
Analyst	Buy

Ask	65.99
Volume	684,441
Avg. Volume (20D)	1,478,759
Open	64.90
Previous Close	64.85
Day's Range	64.50 - 65.90
52-Week Range	60.63 - 94.85
Beta	undefined

About BMRN

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 26, 1999

Employees 3,401

Stock Exchange NASDAQ

Ticker Symbol BMRN

Website https://www.biomarin.com

Full Company Profile

Analyst Forecast

According to 21 analyst ratings, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is $90, which is an increase of 38.44% from the latest price.

Buy 71.43%

Hold 28.57%

Sell 0.00%

Stock Forecasts

Next Earnings Release

BioMarin Pharmaceutical Inc. is scheduled to release its earnings on Feb 19, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 months ago

-17.71%

BioMarin Pharmaceutical shares are trading lower f... Unlock content with Pro Subscription

5 months ago

-5.27%

BioMarin Pharmaceuticals shares are trading lower after Truist Securities lowered its price target on the stock from $140 to $118.

News

1 day ago · zacks.com

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.

1 day ago · zacks.com

BioMarin to Report Q4 Earnings: Here's What to Expect

When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.

5 days ago · zacks.com

Unveiling BioMarin (BMRN) Q4 Outlook: Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of BioMarin (BMRN) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for ...

6 days ago · zacks.com

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks ...

6 days ago · zacks.com

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · zacks.com

3 Reasons Growth Investors Will Love BioMarin (BMRN)

BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

2 weeks ago · zacks.com

4 Stocks That Sport Impressive Interest Coverage Ratio

BMRN, CAKE, LDOS & ENSG's impressive interest coverage ratios highlight that these companies can withstand financial hardships.

3 weeks ago · zacks.com

BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents i...

3 weeks ago · zacks.com

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

3 weeks ago · seekingalpha.com

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

BioMarin's stock has dropped over 26% since July 2024, raising questions about whether it's a bargain or a falling knife. Key issues include valuation, stock volatility, an underwhelming investor's da...

Load More News